The questions people ask — answered plainly.

No. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Stem-cell products marketed for hair or skin are not FDA-approved. Ask any provider about the FDA status of what they offer.

PRP uses concentrated platelets from your own blood, while stem cell products are made from cell-containing tissues such as fat or umbilical cord. They are different things, though clinics sometimes market them together. Neither is a guaranteed solution, and a licensed clinician can explain what is being used.

No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Evidence for cosmetic uses is limited or investigational. Ask a provider for the product's regulatory status in writing.

Microneedling is an established procedure offered by licensed providers, but how well it suits a given concern varies from person to person. A provider can discuss what is known, what is uncertain and whether it fits your situation. No outcome can be promised.

Confirm the clinician's license with your state medical board and ask for the FDA status of every product. If a study is involved, verify it is registered on ClinicalTrials.gov with IRB oversight. Expect written informed consent that covers risks and alternatives.

Be cautious of cure-all claims, being asked to pay to join a 'clinical trial', testimonials used instead of evidence, and pressure to travel abroad or across states. Calling a treatment 'holistic' or 'alternative' does not change its FDA status. Take your time and talk with a licensed clinician.

No. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Stem cell therapy offered for tendon or ligament injuries is generally not FDA-approved, so ask any provider about the exact product's regulatory status.

There is no established evidence that it does, and no one should promise it. Research in this area is limited or investigational. A licensed clinician can explain what is known and unknown for your situation.

No reputable provider can promise that. Whether surgery, rehabilitation, or another approach fits depends on your injury and an in-person evaluation. Ask for all options, including alternatives, in writing.

No. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome and stem cell products. Be cautious with clinics that market them as proven.

Verify the clinician's license with your state medical board and ask about the product's FDA status. If a study is mentioned, confirm it is registered on ClinicalTrials.gov with IRB oversight, and get written informed consent covering risks and alternatives. Be wary of paying to join a 'trial' or of testimonials replacing evidence.

Sports medicine physicians, orthopedic specialists, and physical therapists are common starting points, and some practices also offer orthobiologics or regenerative medicine. Choose a licensed clinician who explains all options honestly. Providers.plus lists licensed providers you can explore.

No. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Stem cell injections marketed for back or neck pain are generally not FDA-approved, so ask any provider about the product's regulatory status.

The evidence is limited and still investigational, and no outcome can be promised. Some people explore it, but research is ongoing. A licensed spine or pain specialist can explain what is known and what other options may fit your situation.

No. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Ask a licensed clinician about risks and be cautious about marketing claims.

A good starting point is often a primary care clinician or a spine or interventional pain specialist. Orthopedic regenerative medicine providers may also discuss orthobiologics. Confirm any clinician's license with your state medical board.

Verify the product's FDA status, confirm the clinician's license, and ask for written informed consent covering risks and alternatives. Be wary of cure-all claims, testimonials in place of evidence, and pressure to travel for treatment.

A legitimate study is registered on ClinicalTrials.gov and overseen by an institutional review board (IRB). Be cautious if you are asked to pay to join a trial. A licensed clinician can help you understand whether a study is appropriate for you.

Only a narrow set of stem-cell products is FDA-approved in the U.S.: cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell therapy products, including MSC, adipose/SVF, umbilical cord, Wharton's jelly and perinatal products, are not FDA-approved. Ask any provider about the exact FDA status of what they are offering.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products marketed by some clinics. Ask a licensed clinician about the regulatory status and any risks before considering one.

Start by confirming the clinician's license with your state medical board and asking whether the product is FDA-approved. If the clinic says it is a study, check that it is registered on ClinicalTrials.gov and has IRB oversight. Also ask for written informed consent that explains risks and alternatives.

Common red flags include claims that a treatment cures or treats everything, being asked to pay to join a clinical trial, and testimonials used in place of evidence. Pressure to travel abroad or across states, or to decide quickly, is another warning sign. Calling a practice holistic or alternative does not change a product's FDA status.

Ask what the product is, whether it is FDA-approved, what the evidence is and how limited it may be, and what the risks and alternatives are. Ask who will perform the procedure and whether they are licensed. It also helps to get a second opinion from another licensed clinician.

No one can promise that it will, and families should be cautious about any claim that a treatment avoids surgery or regrows tissue. Evidence for many clinic uses is limited or investigational. A licensed clinician who has evaluated your loved one is the right person to discuss options and alternatives.

Stem cell therapy is a broad term for treatments that use stem cells, which are cells able to develop into other cell types. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Many other uses are experimental or unapproved.

Only in a narrow area: cord-blood-derived hematopoietic progenitor cell products for certain blood and immune disorders, used in specialist transplant settings. Most clinic offerings, including MSC, adipose/SVF, umbilical cord, Wharton's jelly and perinatal products, are not FDA-approved. Ask any provider to show you how to verify a product's status.

No. Holistic or alternative framing never changes FDA status. A product that is not approved remains unapproved no matter how it is described, so it is reasonable to ask about its regulatory status directly.

No, no exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Research is ongoing, but evidence for clinic uses is limited. Talk with a licensed clinician before considering any such product.

Confirm the clinician's license with your state medical board, ask about the product's FDA status, and check that any study is registered on ClinicalTrials.gov with IRB oversight. Request written informed consent covering risks and alternatives. Be cautious of cure-all claims, fees to join a "trial," testimonials instead of evidence, and pressure to travel.

An integrative provider may help you understand your options, review your history and discuss both conventional and complementary approaches. They may also help you ask informed questions about evidence and safety. No outcome is promised, and a licensed clinician makes any recommendation after an evaluation.

Stem cell therapy for joint pain generally means injecting cells or cell-derived products, often from your own bone marrow or fat or from donated tissue, into or near a painful joint. These uses are mostly investigational, and evidence is limited. A licensed clinician can explain what is and is not known.

No, stem cell therapy is not FDA-approved for knee, hip or shoulder pain. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. The FDA has also warned the public about unapproved stem cell products.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products marketed for a range of conditions. Ask any provider offering them about the product's regulatory status and risks.

The evidence is limited and still being studied, so it is not possible to say it works for any given person. Research is ongoing and results have varied. A licensed clinician can discuss what is known and what established alternatives exist.

Start by confirming the clinician's license with your state medical board and asking whether the product is FDA-approved. If a study is involved, check that it is registered on ClinicalTrials.gov with IRB oversight, and ask for written informed consent covering risks and alternatives. Be wary of cure-all claims, fees to join a "clinical trial," testimonials in place of evidence, and pressure to travel.

Orthopedic, sports medicine and orthobiologics clinicians are often the ones who discuss these options, and some physicians offer adipose-derived cell procedures. Start with a licensed provider who will examine you and explain the risks, alternatives and regulatory status. You can look for licensed providers through Providers.plus.

Start by searching ClinicalTrials.gov, the U.S. registry of studies, and ask your own doctor or a specialist to help you review options. University medical centers, hematology and transplant centers, and MSC clinical research sites may also run registered studies. Always confirm the listing details before contacting a site.

Check that the study has a ClinicalTrials.gov listing, that an IRB oversees it, and that the sponsor and location match what the clinic tells you. Confirm the clinician's license with your state medical board, and ask about the product's FDA status. A real study should provide written informed consent covering risks and alternatives.

Being asked to pay to join a 'clinical trial' is a recognized red flag. Legitimate research is generally structured and funded differently from a clinic selling a service, though a research team can explain exactly what costs, if any, apply to you. If you are unsure, ask your own doctor to review the offer before you agree to anything.

In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic offerings, including MSC, adipose/SVF, umbilical cord, Wharton's jelly and perinatal products, are not FDA-approved. The FDA has also warned the public about unapproved stem cell products.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products marketed by some clinics. Ask a licensed clinician about the regulatory status of anything you are offered.

Ask for the ClinicalTrials.gov number, the name of the overseeing IRB, the product's FDA status, and the known and possible risks and alternatives. Request written informed consent and time to review it with your own doctor. You should also be told that you may leave a study at any time.

A fat stem cell injection is a procedure in which a person's own fat tissue is collected, processed and then placed in another part of the body, such as near a joint. In the U.S., these adipose-derived products are not FDA-approved for treating joint conditions. A licensed clinician can explain what a specific offering involves and what is known about it.

Stromal vascular fraction is a mixture of cells separated from fat tissue, often using enzymes or mechanical processing. It contains several cell types, not only stem cells. SVF products used in clinics are not FDA-approved, and the FDA has warned the public about unapproved stem cell products.

Microfragmented adipose tissue is fat that has been broken into smaller pieces while keeping much of its natural structure. Lipogems is a brand name for one system that does this. Ask a provider about the FDA status of any such use for joints, because it is not approved for treating joint conditions and evidence is limited.

Processing can change how the FDA classifies a product. Tissue that is only minimally handled and used in the same procedure may be regulated differently than tissue that is separated, enzymatically treated or grown, which is generally treated as a drug or biologic needing approval. Ask your provider to explain how they believe their product is regulated, and verify it yourself.

They are cells collected from different tissues, fat versus bone marrow, using different collection methods, and they differ in what they contain. Neither is FDA-approved for joint conditions, and evidence for both is limited or investigational. A licensed clinician can discuss whether either is appropriate after an evaluation.

Start by verifying the clinician's license with your state medical board and asking whether the product is FDA-approved. Check that any study is registered on ClinicalTrials.gov with IRB oversight, and get written informed consent covering risks and alternatives. Be cautious of cure-all claims, fees to join a trial, testimonials in place of evidence, and pressure to travel.

Bone marrow aspirate concentrate (BMAC) is a preparation made by drawing bone marrow from a person's own body, often the hip, and spinning it in a centrifuge to concentrate certain components. It may contain blood cells, platelets, signaling proteins and some progenitor cells. It is investigational for most uses and not a guaranteed treatment.

No, BMAC used for injections such as in joints is not an FDA-approved product. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, and the FDA has warned the public about unapproved stem cell products. Ask your clinician about the regulatory status of anything offered to you.

A BMAC injection in the knee is an investigational approach in which concentrated bone marrow from the person's own body is injected into or around the joint by a clinician. Evidence for it is limited, and it is not FDA-approved for this use. A licensed clinician must evaluate you to decide whether any procedure is appropriate.

BMAC procedure recovery varies from person to person and depends on the clinician's approach and the area treated. Because marrow is collected and an injection is given, people often ask about soreness and activity limits. Ask your clinician what to expect for your situation and what warning signs should prompt a call.

BMAC comes from bone marrow, while platelet-rich plasma (PRP) is made from a blood draw that is concentrated for platelets. They are different preparations with different collection steps. Neither is guaranteed to work, so ask a licensed clinician how each is regulated and which, if either, fits your situation.

A bone marrow stem cell injection carries risks like any procedure, and because most such products are not FDA-approved, safety and effectiveness are not established the way they are for approved treatments. Ask for written informed consent covering risks and alternatives, confirm the clinician's license, and check whether any study is registered on ClinicalTrials.gov with IRB oversight.

No. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Stem cell therapy marketed for knee pain is generally not FDA-approved. Ask a licensed clinician about the regulatory status of any product.

The evidence is limited or investigational, and no outcome can be promised. Research is ongoing, and results vary by person, product, and condition. A licensed clinician can explain established options alongside any regenerative ones.

Some clinics offer stem cells for rotator cuff problems, but these offerings are mostly not FDA-approved and the evidence is limited. Traditional care often begins with an evaluation and rehabilitation. Ask a provider about options, risks, and alternatives.

Orthobiologics are substances derived from the body's own biology, such as PRP or cell-based preparations, that some clinicians use for musculoskeletal problems. Their regulatory status and evidence vary, and many cell-based products are not FDA-approved. A sports medicine clinician can explain what applies to your situation.

No, these uses are not proven and are not FDA-approved. Evidence is limited or investigational, and the FDA has warned about unapproved stem cell and exosome products. A board-certified dermatologist can discuss established options and how to evaluate newer claims.

Start by confirming the clinician's license with your state medical board. Ask whether the product is FDA-approved, whether any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Be wary of cure-all claims, paying to join a 'trial', testimonials instead of evidence, and pressure to travel.

Start by asking each clinic for the exact product used and its FDA status, then confirm the clinician's license with your state medical board. Ask for written informed consent covering risks and alternatives, and whether any study is registered on ClinicalTrials.gov. Comparing answers, rather than marketing, is the safest approach.

Only in limited cases. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell therapy offerings are not FDA-approved, and the FDA has warned the public about unapproved products.

Common red flags include claims that a treatment cures or treats many unrelated conditions, requests to pay to join a clinical trial, and testimonials used instead of evidence. Pressure to decide quickly or to travel abroad or across states is another warning sign. Any of these is a reason to pause and seek an independent opinion.

Search ClinicalTrials.gov for the study and check that it matches what the clinic describes. Ask whether an institutional review board (IRB) oversees it and request the consent documents. Legitimate research generally does not charge participants to take part, so be cautious if you are asked to pay.

No. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. If a clinic offers them, ask about the product's regulatory status and talk with an independent licensed clinician before deciding.

No. Regenerative medicine refers to approaches aimed at supporting repair, some established and many still investigational, while alternative medicine describes practices outside conventional care. Either label, including holistic, does not change a product's FDA status, so verify it the same way.

Exosomes in regenerative medicine are tiny particles released by cells that carry signaling materials such as proteins and genetic material. They are not living cells and are different from stem cells. Research is ongoing, and most uses remain investigational.

No, exosome treatments are not FDA-approved. No exosome product has FDA approval, and the FDA has warned the public about unapproved exosome and stem cell products. Ask any provider about a product's regulatory status before considering it.

An exosome injection is a product marketed by some clinics that contains exosome preparations given by injection. These products are not FDA-approved, and evidence for their use is limited or investigational. A licensed clinician must decide what is appropriate after an evaluation, and you should ask about risks and alternatives.

There is no FDA-approved exosome product for hair, and evidence is limited or investigational. Marketing for exosomes for hair often goes beyond what research has shown. A licensed clinician can evaluate the cause of your hair concerns and discuss options with an established track record.

Exosome IV therapy is not FDA-approved, and its safety has not been established through the FDA approval process. The FDA has warned the public about unapproved exosome products. Talk with a licensed clinician about risks, and be cautious about any provider who downplays them.

Exosomes vs mesenchymal stem cells comes down to living cells versus particles. Mesenchymal stem cells (MSCs) are cells, while exosomes are small particles that cells release. Neither is FDA-approved for the uses commonly advertised by clinics, so ask about regulatory status and check for registered, IRB-overseen studies.

Mesenchymal stem cells (MSCs) are cells found in tissues like bone marrow, fat, and umbilical cord that researchers study for their possible roles in repair and cell signaling. In a lab they can develop into cell types such as bone, cartilage, and fat. How they behave in the human body is still being investigated.

The terms are often used interchangeably, but many scientists prefer 'stromal cells' because it is debated whether these cells act as true stem cells in the body. Some of their possible effects may come from signals they release rather than from becoming new tissue. Ask a provider exactly what is meant when a product is described either way.

No, in the U.S. MSC products are not FDA-approved for treating conditions. The only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask any provider about a product's regulatory status.

The evidence for MSC therapy for joints is limited and investigational, so no one can promise a result. Research is ongoing, and findings from early studies do not guarantee the same outcomes for any individual. A licensed clinician can discuss your situation, established options, and any registered clinical trials.

Culture-expanded stem cells are cells that have been collected and grown in a laboratory to increase their number before use. This extra processing raises added questions about safety, quality control, and regulation. Ask whether a product is FDA-approved or being studied under an FDA-regulated and IRB-overseen trial.

MSC injection side effects can include pain, swelling, or infection at the injection site, and reactions to the cells or other materials, and the full range of risks is not well established for unapproved products. Serious problems have been reported with some unapproved stem cell products, which is part of why the FDA has issued warnings. Ask a licensed clinician for written informed consent that covers risks and alternatives before any decision.

PRP therapy is a procedure that uses platelet-rich plasma, a concentrated portion of your own blood, in an effort to support the body's natural repair processes. Blood is drawn, spun in a centrifuge, and the platelet-rich portion is used by a clinician. Evidence varies by use, and a licensed clinician can explain whether it is appropriate for you.

No, PRP is not the same as stem cell therapy. PRP is a concentration of platelets from your blood, while stem cell products involve different cell types. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, and the FDA has warned about unapproved stem cell and exosome products.

The evidence for PRP injection for tendons is described as mixed and still being studied, so no outcome can be promised. Some people and clinicians report interest in it, while others point to inconsistent research. Ask a licensed clinician how it compares with conventional options for your situation.

PRP for knee arthritis is an area of ongoing investigation, and it is not a cure or a proven way to regrow cartilage. Research findings have varied, and it is generally considered off-label. A licensed clinician can discuss the evidence, risks and alternatives, including conventional care.

Leukocyte-poor and leukocyte-rich PRP differ in how many white blood cells remain in the prepared sample. Clinicians sometimes consider this when choosing a preparation, and researchers continue to study whether it matters for different uses. Ask your provider which type they use and why.

PRP injection aftercare is set by your clinician, so follow the written instructions you are given rather than general advice. Instructions commonly address activity, discomfort and what symptoms should prompt a call. Ask about this before the procedure, and seek urgent care or call 911 for an emergency.

Only cord-blood-derived hematopoietic progenitor cell (HPC) products are FDA-approved, and they are used for certain blood and immune disorders in specialist transplant settings. Most other umbilical cord stem cell therapy offered by clinics is not FDA-approved. The FDA has warned the public about unapproved stem cell products, so ask a provider to explain the status of any product.

Wharton's jelly stem cells are cells derived from the gel-like tissue inside the umbilical cord. Wharton's jelly products marketed by clinics are generally not FDA-approved, and evidence for their use is limited or investigational. Ask a licensed clinician and verify any claims before considering one.

Approved cord blood stem cell uses are limited to HPC products for certain blood and immune disorders, given in specialist transplant settings. Other uses are being studied in research, but evidence is limited. A transplant specialist can explain whether this applies to a specific situation.

A perinatal tissue allograft is tissue from a donor's birth-related sources, such as amniotic membrane or placenta, used in another person. How it is regulated depends on how it is processed and intended to be used. Ask a provider whether a specific product is FDA-approved or offered under a registered study.

Donor (allogeneic) stem cells come from another person, while your own (autologous) cells come from your body. They differ in sourcing, processing, safety considerations and regulation. Neither label makes a product FDA-approved, so ask a licensed clinician about the specific product and its risks.

Verify the product's FDA status, confirm the clinician's license with your state medical board, and check that any study is registered on ClinicalTrials.gov with IRB oversight. Ask for written informed consent covering risks and alternatives. Be cautious of cure-all claims, fees to join a trial, testimonials instead of evidence, and pressure to travel.

Adipose-derived cell procedures are treatments that use a person's own fat tissue, or cells separated from it, and place them elsewhere in the body. They include fat grafting, microfragmented adipose tissue, and cell-based products made from fat. Their regulatory status and level of evidence vary, so ask a licensed clinician.

No, processed or expanded fat-derived cell products are generally regulated as drugs/biologics and are not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell products for certain blood and immune disorders. The FDA has warned the public about unapproved stem cell products.

Fat grafting generally means moving fat from one area of the body to another, while microfragmented adipose tissue is fat broken into smaller pieces. Both may be described differently by different clinics. Ask a provider exactly how the tissue is handled and how it is regulated.

Some clinics offer fat-based stem cell therapy for joint pain, but evidence is limited or investigational and these uses are not FDA-approved. Results are not guaranteed, and these options should not be assumed to avoid surgery. A licensed clinician can discuss established alternatives and risks.

Start by confirming the clinician's license with your state medical board and asking about the product's FDA status. Check whether any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Be cautious of high-pressure sales or testimonial-driven claims.

Ask whether the product is FDA-approved, what the risks and alternatives are, and what evidence supports its use for your situation. Ask who performs the procedure and how their license can be verified. Take your time, since a reputable provider should not pressure you.

Aesthetic and hair regenerative care is a broad label for services such as PRP, microneedling and exosome-marketed products that people explore for hair thinning, skin texture and facial rejuvenation. Some are established procedures used in various settings, while others are unapproved products. A licensed clinician can explain which is which.

No, stem cell therapy for hair and skin is not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Ask any provider about the FDA status of what they offer.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products. If a clinic offers them, ask about regulatory status, risks and whether any study is registered on ClinicalTrials.gov with IRB oversight.

PRP is platelet-rich plasma, made by concentrating platelets from a person's own blood sample. Exosomes are tiny cell-released particles in products that are generally unapproved. The two are different, and a provider should be able to explain what they use and its regulatory status.

Microneedling is a procedure that uses fine needles to make tiny pricks in the skin, while PRP is a blood-derived preparation. They are sometimes used together. Evidence for specific uses can be limited, and results are not guaranteed.

Start by confirming the clinician's license with your state medical board and asking about the FDA status of every product. Request written informed consent covering risks and alternatives. Be wary of cure-all claims, testimonials in place of evidence, paying to join a "clinical trial," or pressure to travel for treatment.

A hematology and transplant center is a specialist hospital program that cares for blood, bone marrow and immune conditions. Physician-led teams may evaluate whether a hematopoietic stem cell transplant or cord blood transplant is appropriate. Only a licensed clinician can make that decision.

Only a narrow set of stem cell products is FDA-approved in the U.S.: cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Most other products marketed as stem cell therapy are not approved, and the FDA has warned the public about them. Ask any provider about a product's FDA status.

Both are forms of hematopoietic stem cell transplant, and they differ mainly in the source of the cells. Cord blood transplant uses blood collected from the umbilical cord after birth, while other transplants may use cells from bone marrow or circulating blood. A transplant team can explain which source, if any, may be considered.

No. Transplant centers are specialist hospital settings that use FDA-approved cord blood HPC products for specific blood and immune disorders. Many retail clinics offer unapproved products, and a 'holistic' or 'alternative' label does not change a product's FDA status.

Start by asking whether a transplant is appropriate for your condition and what the alternatives are. Ask about the cell source and its FDA status, the risks, the follow-up care and the team's experience. You may also ask about written informed consent and getting a second opinion.

Confirm the clinician's license with your state medical board and check that any study is registered on ClinicalTrials.gov with IRB oversight. Be cautious about cure-all claims, fees to join a 'clinical trial', testimonials in place of evidence, or pressure to travel. Always get written informed consent that covers risks and alternatives.

Stem cell therapy in an integrative setting usually means a clinic offers cell-based products alongside nutrition, lifestyle and other supportive services. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Most other clinic stem cell offerings are not FDA-approved, so ask a licensed clinician about the status of any product.

No, holistic or alternative framing does not change a product's FDA status. A product is either approved, authorized for study, or unapproved regardless of how a practice describes itself. Ask the provider directly and verify the answer.

No, PRP is different from stem cell therapy. PRP is a concentrate prepared from a person's own blood platelets, while stem cell products involve cells from other sources. Evidence for many PRP uses is limited or still being studied, so a licensed clinician can explain what applies to you.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome and stem cell products. Be cautious about any clinic that presents them as proven.

Start by confirming the clinician's license with your state medical board. Ask about the FDA status of every product, and whether any study is registered on ClinicalTrials.gov with IRB oversight. Request written informed consent that covers risks and alternatives.

Ask what the evaluation includes, what the evidence is and how limited it may be, what the risks and alternatives are, and how care will be coordinated with your other clinicians. A good provider will answer plainly and give you time to decide. No provider can guarantee a result.

An MSC clinical research site is a physician-led practice, hospital, or academic center that studies mesenchymal stromal cells under a written protocol. Legitimate sites register studies on ClinicalTrials.gov and operate with IRB oversight. The work is investigational, meaning the cells are being studied rather than offered as proven care.

No, MSC treatments are not FDA-approved for general clinic use. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask any provider about a product's regulatory status.

A legitimate trial is registered on ClinicalTrials.gov and overseen by an IRB. You can look up the registration number yourself, confirm the clinician's license with your state medical board, and review written informed consent materials. If anything cannot be verified, consider that a reason to pause.

Paying to join a so-called trial is a red flag. Legitimate research generally does not charge participants for the investigational product itself, though study details vary, so ask the team to explain in writing what you would be responsible for. Be cautious of anyone who blurs the line between research and a paid treatment.

Informed consent is a written document and conversation that explains a study's purpose, possible risks, alternatives, and your right to leave at any time. You should receive it to review before deciding, and you can ask questions. It should never be rushed or used to pressure you.

No, no exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Claims that exosomes treat a wide range of conditions should be viewed with caution. Ask a licensed clinician about the regulatory status and any registered research.

Orthopedic regenerative medicine is a group of approaches, such as PRP, BMAC and image-guided injections, that some physician-led practices use for joint and soft-tissue concerns. Most are not FDA-approved for these uses, and evidence is limited or investigational. A licensed clinician can explain what applies to you.

No, stem cell therapy for knee arthritis is not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Ask any provider about the FDA status of what they offer.

BMAC stands for bone marrow aspirate concentrate, a preparation made by processing a sample of a person's own bone marrow. Its use in orthopedic settings is not an FDA-approved treatment, and evidence is limited. Ask a clinician about risks, alternatives and current regulatory status.

PRP is made by concentrating platelets from your blood, while stem cell preparations such as BMAC come from tissue like bone marrow. They are different materials with different processing and regulatory considerations. Neither should be assumed to regrow cartilage, and a clinician can explain how each is classified.

No one can promise that any injection will avoid surgery. Evidence for these approaches is limited or investigational, and individual situations differ. A licensed clinician or surgeon can discuss all your options, including conventional care.

Confirm the clinician's license with the state medical board, ask about the FDA status of any product, and get written informed consent covering risks and alternatives. If a study is involved, check that it is registered on ClinicalTrials.gov with IRB oversight. Be wary of cure-all claims, paying to join a 'trial', testimonials instead of evidence, and pressure to travel.

In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products, used in specialist transplant settings for certain blood and immune disorders. Most umbilical cord products sold by clinics for joints or general wellness are not FDA-approved. The FDA has warned the public about unapproved stem cell products, so ask any provider about a product's status.

Wharton's jelly is the gelatin-like tissue inside the umbilical cord, and products made from it are donor-derived allografts. After processing, many contain no living cells. Most are not FDA-approved for orthopedic or whole-body uses, so ask the provider what the specific product contains.

Often they do not. Many amniotic and placental products are processed in ways that leave no living cells, even when marketed as "stem cell therapy." Ask for documentation of what the product contains, and check its FDA status.

Only a licensed clinician can discuss safety for your situation after an evaluation. Evidence for many donor-tissue injections is limited or investigational, and unapproved products carry uncertainties. Ask about risks and alternatives, and get written informed consent.

Start with documented facts rather than marketing: the tissue source, how it was processed, whether it contains living cells, and its FDA status. Ask the provider to explain why they chose that product and what the alternatives are. A second opinion can also help.

Confirm the clinician's license with your state medical board and ask whether the product is FDA-approved. If a study is involved, check that it is registered on ClinicalTrials.gov with IRB oversight. Be cautious of cure-all claims, fees to join a "trial," testimonials in place of evidence, or pressure to travel for treatment.

No, stem cell therapy for back pain is not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Ask any provider about the FDA status of a specific product.

An interventional pain physician evaluates pain, often related to the spine, and may use tools such as image-guided injections as part of a broader plan. They may also coordinate with other professionals like physical therapists or surgeons. What is appropriate depends on your evaluation.

It is a procedure in which a clinician uses live imaging, such as fluoroscopy or ultrasound, to help place medication near a targeted area. The goal of imaging is to guide placement. Whether it is suitable for you is a decision for a licensed clinician.

Evidence for PRP in spine conditions is limited or investigational, and results are not guaranteed. PRP is made from your own blood, but how it is prepared and used can vary, and use for spine pain is often outside FDA-approved indications. Ask a clinician about the current evidence and the risks.

No, no exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. If a clinic offers them, ask for written information on regulatory status, risks and alternatives.

Confirm the clinician's license with your state medical board and ask whether the product is FDA-approved. If a study is involved, check that it is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Be cautious of cure-all claims or pressure to pay quickly.

Stem cell therapy in sports medicine usually refers to injections made from cells or tissues, such as bone marrow, fat or birth-related material, that clinics offer for joint and tendon problems. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Most clinic uses for injuries are not FDA-approved and are limited or investigational, so ask a licensed clinician about the status.

No, PRP and stem cell therapy are different. PRP is made by concentrating platelets from your own blood, while stem cell products are made from other cell sources. Both are discussed in orthobiologics, and evidence for each varies, so ask a clinician what is known about your situation.

No, there is no FDA-approved stem cell therapy for tendon or ligament injuries. The only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. The FDA has also warned the public about unapproved stem cell and exosome products, and no exosome product is FDA-approved.

An ultrasound-guided injection is a procedure where a clinician uses live ultrasound imaging to see the area while placing a needle. The imaging is meant to help with accuracy. Whether an injection is appropriate, and what goes in it, is a decision for a licensed clinician after an evaluation.

Start by confirming the clinician's license with your state medical board and asking about their training. Ask for written informed consent covering risks and alternatives, and check any claimed study on ClinicalTrials.gov for IRB oversight. Be cautious about cure-all claims, paying to join a trial, testimonials in place of evidence, or pressure to travel for treatment.

A provider may help by evaluating the problem, explaining options and coordinating rehabilitation, though no outcome is guaranteed. Care for tennis elbow and return to sport often centers on a guided, gradual approach tailored to you. A licensed clinician decides what is appropriate after an exam.

Adipose cell injection for joints is a procedure in which cells or tissue from a person's own body fat are processed and injected into a joint. Clinics may call the material adipose-derived stem cells, SVF or micro-fragmented fat. Evidence for joint uses is limited, and these products are generally not FDA-approved.

No, adipose cell injection for joints is generally not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Ask any provider about the specific product's FDA status.

No one can promise that. Claims of cartilage regrowth or avoiding surgery are not established, and evidence is limited or investigational. A licensed clinician can discuss realistic possibilities and alternatives after evaluating you.

Confirm the clinician's license with your state medical board, and ask whether the product is FDA-approved. If the offering is research, check that it is registered on ClinicalTrials.gov with IRB oversight. Be cautious of cure-all claims, testimonials instead of evidence, and pressure to travel.

Be very cautious, because paying to join a so-called clinical trial is a recognized red flag. Legitimate research is registered on ClinicalTrials.gov and has IRB oversight. Ask for the registration details and written informed consent before agreeing to anything.

Start by asking about FDA status, the evidence for your situation, the risks, and the alternatives. Ask for written informed consent that covers all of these. A licensed clinician can decide what is appropriate for you after an evaluation.

The main difference is where the cells come from: adipose cells are taken from fat tissue, while bone marrow cells are taken from the center of bones. They contain different mixes of cells and are collected and processed differently. Whether one is better for a particular purpose is not established, and a licensed clinician can explain what applies to you.

Generally no, for clinic-based uses. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask any provider about the FDA status of what they offer.

There is no established answer that one source is better. Evidence for many uses of both is limited or investigational, and results cannot be promised. A licensed clinician can discuss your situation, the evidence, and alternatives after an evaluation.

Using your own cells does not automatically make a treatment safe or approved. Risks can include infection, discomfort at the collection or injection site, and problems from poor handling or unproven products. Ask a licensed clinician about risks and get written informed consent covering risks and alternatives.

Start by confirming the clinician's license with your state medical board and asking about the product's FDA status. If a study is mentioned, check that it is registered on ClinicalTrials.gov with IRB oversight. Be cautious about cure-all claims, fees to join a 'trial', testimonials instead of evidence, and pressure to travel.

This cannot be promised. Claims of tissue or cartilage regrowth, or of avoiding surgery, are not established for clinic-offered stem cell products, and evidence is limited or investigational. Talk with a licensed orthopedic or other clinician about the full range of options.

Alternative medicine describes approaches used in place of conventional care, while regenerative medicine is a scientific field focused on repairing or replacing tissue. They are different concepts, but some clinics use both words together. Neither label tells you whether a treatment is proven or FDA-approved.

Stem cell therapy is not inherently alternative medicine. It is a part of regenerative medicine research and, in specific cases, established transplant care. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, and most clinic offerings are not approved.

Regenerative medicine as a whole is not a single approved treatment, so approval depends on the specific product and use. Most clinic stem cell, MSC, adipose, umbilical cord, Wharton's jelly, perinatal and exosome products are not FDA-approved. Ask a provider about the exact FDA status of anything offered.

No, holistic or natural framing does not change a product's FDA status or its risks. An unapproved product remains unapproved however it is described. Ask for the same information about safety, evidence and consent that you would for any treatment.

Verify the product's FDA status, confirm the clinician's license with your state medical board, and check that any study is registered on ClinicalTrials.gov with IRB oversight. Ask for written informed consent covering risks and alternatives. Be cautious about cure-all claims, fees to join a 'trial', testimonials instead of evidence, and pressure to travel.

No, no provider can honestly promise results, tissue regrowth or that a treatment will avoid surgery. Evidence for many clinic-based uses is limited or investigational. A licensed clinician can discuss what is known and what your options are.

No. In the U.S., no exosome product is FDA-approved for any use. The FDA has warned the public about unapproved stem cell and exosome products. Ask any provider to explain the regulatory status of what is being offered.

Some clinics market exosome products despite the lack of approval, and this is a reason for caution. Marketing claims do not equal FDA approval or strong evidence. A licensed clinician should be able to tell you plainly what the product is and what its status is.

No. Exosomes are tiny particles released by cells, while stem cells are whole cells. The only FDA-approved stem-cell products in the U.S. are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings.

Evidence in people is limited and mostly investigational. Be wary of testimonials or before-and-after stories offered in place of evidence. A licensed clinician can help you understand what is and is not established.

Look for the study on ClinicalTrials.gov and confirm it has IRB oversight. Be cautious if you are asked to pay to join a 'clinical trial'. You can also confirm the clinician's license with your state medical board.

Ask what the product is, who makes it, and what its FDA status is. Ask about risks, alternatives, and whether you will receive written informed consent. Only a licensed clinician can decide what is appropriate for you after an evaluation.

A BMAC injection for the knee is a procedure in which a clinician draws bone marrow, concentrates it, and injects the concentrate into or around the knee. It uses the person's own marrow. It is not an FDA-approved stem-cell product, and evidence for knee use is limited or investigational.

No, BMAC for the knee is not an FDA-approved stem-cell product. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Ask any provider about the FDA status of what they offer.

BMAC is often described as a type of stem cell therapy, but it is a mixed concentrate rather than a purified stem-cell product. It may contain various cells and proteins. The term is used loosely, so ask a provider exactly what is in the preparation and how it is regulated.

No one can promise that. Claims of cartilage regrowth or avoiding surgery are not established, and research is limited. Whether surgery or another option is appropriate is a decision for you and a licensed clinician after an evaluation.

Ask whether the product is FDA-approved for your condition, whether any study is on ClinicalTrials.gov with IRB oversight, and whether the clinician's license is current with the state medical board. Also ask about risks, alternatives, and request written informed consent.

Red flags include cure-all or 'treats everything' claims, being charged to join a 'clinical trial', and testimonials used instead of evidence. Pressure to travel abroad or across states is another warning sign. The FDA has warned the public about unapproved stem cell and exosome products.

It varies from person to person and depends on your clinician's approach, so your provider is the best source. People are commonly given written aftercare instructions that cover soreness, activity and follow-up. Ask your clinician what to expect for your situation.

No, BMAC used for joint, tendon or other musculoskeletal concerns is not an FDA-approved stem cell product. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Ask any provider about the FDA status of what they offer.

Your licensed clinician decides, based on your evaluation and health history. Online information cannot replace personal instructions. Ask for aftercare guidance in writing and find out who to contact with concerns.

Ask about FDA status, risks, alternatives, what recovery involves, and who handles follow-up. If it is offered as research, confirm it is registered on ClinicalTrials.gov with IRB oversight. Verify the clinician's license with your state medical board and request written informed consent.

No one can promise that a treatment avoids surgery, and evidence for BMAC is limited or investigational for many uses. Whether surgery or another approach is appropriate is a decision for you and a licensed clinician. Ask for a clear discussion of all your options.

Be cautious about cure-all claims, being asked to pay to join a 'clinical trial', testimonials used instead of evidence, and pressure to travel abroad or across states. The FDA has warned the public about unapproved stem cell and exosome products. Take your time and talk with a licensed clinician.

The main difference is the source. BMAC is concentrated from bone marrow, while PRP is concentrated from blood and is rich in platelets. They contain different components and are collected differently, and neither is an FDA-approved stem-cell treatment for orthopedic uses.

BMAC is often marketed as a "stem cell therapy," but it is a mixed preparation with many cell types and signaling proteins. It is not FDA-approved as a stem-cell treatment for orthopedic uses. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Ask a provider what the product contains and how it is regulated.

No, PRP is not generally considered a stem cell treatment. It is made from your blood and concentrates platelets, not bone marrow cells. A clinician can explain how it is prepared and how it is regulated.

Neither can be called better in general, and this page cannot say which suits any person. The right choice, if either, depends on your condition, history and goals, and evidence for both is mixed or still developing for many uses. A licensed clinician can discuss options, including non-biologic ones, after an evaluation.

BMAC and PRP for orthopedic uses are not FDA-approved stem-cell treatments. The FDA has warned the public about unapproved stem cell and exosome products. Ask any provider about the FDA status of what they offer and request it in writing.

Look for a licensed clinician in orthopedic regenerative medicine or sports medicine, and confirm the license with your state medical board. Ask about regulatory status, risks, alternatives and whether any study is registered on ClinicalTrials.gov with IRB oversight. Get written informed consent, and be wary of cure-all claims or pressure to travel for treatment.

It is a procedure in which a clinician collects a person's own bone marrow, concentrates it, and injects it into a chosen area, often called BMAC. The concentrate contains a mix of components, not only stem cells. Whether it is appropriate is a decision for a licensed clinician after an evaluation.

No, clinic-based bone marrow stem cell injections for joints or pain are not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask any provider about regulatory status.

Evidence is limited or investigational, and no outcome can be promised. Professionals disagree about its role, and research is ongoing. A licensed clinician can explain what is known and what is uncertain for your situation.

It is commonly collected from the hip bone, using a needle, by a trained clinician. The specifics, including comfort measures and risks, vary by provider and patient. Ask your clinician to walk you through the process and put the risks in writing in your consent form.

Start by confirming the clinician's license with your state medical board and asking whether the product is FDA-approved. Check that any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Directories like Providers.plus list licensed providers, but you should still verify credentials yourself.

Be cautious of cure-all or 'treats everything' claims, fees to join a 'clinical trial,' testimonials instead of evidence, and pressure to travel abroad or across states. Any of these is a reason to pause and get a second opinion from an independent licensed clinician.

Cord blood stem cells are used in specialist transplant settings as a source of hematopoietic progenitor cells for certain blood and immune disorders. This is the use that the FDA has approved. A transplant physician decides whether it is appropriate for a given person.

Only cord-blood-derived HPC products are FDA-approved in the U.S., and only for certain blood and immune disorders. Other uses are not approved. Ask any provider to show you the FDA status of the specific product they propose.

No. Cord blood is the blood collected from the umbilical cord and placenta. Cord tissue and Wharton's jelly come from the cord itself, and products made from them are generally not FDA-approved for clinic use.

These uses are not FDA-approved, and evidence for them is limited or investigational. Be cautious about any clinic promising results. Talk with a licensed clinician and look for studies registered on ClinicalTrials.gov with IRB oversight.

This is a personal decision to discuss with your obstetric provider. Families can donate to a public bank or store privately, and each option has different features. Banking does not guarantee that the stored cells will be suitable or needed in the future.

Verify the product's FDA status, confirm the clinician's license with your state medical board, and check that any study is registered on ClinicalTrials.gov with IRB oversight. Ask for written informed consent covering risks and alternatives. Be wary of cure-all claims, fees to join a 'trial', and pressure to travel.

Culture expanded stem cells are cells, often mesenchymal stem cells, that are grown and multiplied in a laboratory after being collected from a source such as bone marrow, fat, or umbilical cord tissue. The goal of expansion is to increase cell numbers. Their use outside of approved or properly overseen research is a topic to discuss with a licensed clinician.

No, culture expanded MSC products offered by clinics are generally not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products.

Culture expanded cells are grown in a lab to increase their number, while other products may be used soon after collection with little or no growth step. The processing differences can affect how a product is regulated and what questions about safety and quality apply. A licensed provider can explain how a specific product is made and its regulatory status.

Evidence is limited and largely investigational, and no cure or specific result can be promised. Researchers continue to study MSCs, but findings do not mean any clinic product is proven or approved. Ask whether a study is registered on ClinicalTrials.gov and overseen by an IRB.

Confirm the clinician's license with your state medical board and ask whether the product is FDA-approved or offered within a registered, IRB-overseen study. Request written informed consent that covers risks and alternatives. Be cautious of cure-all claims, fees to join a 'trial,' testimonials instead of evidence, or pressure to travel.

Ask about the product's FDA status, how the cells are sourced, grown, and tested, and what the known risks and alternatives are. Also ask if there is a registered study and who oversees it. A licensed clinician must evaluate you before deciding what, if anything, is appropriate.

Donor (allogeneic) stem cells come from another person, while your own (autologous) stem cells come from your body. The difference is the source, and each raises different questions about collection, matching, and oversight. A licensed clinician can explain which, if either, is relevant to your situation.

Only certain cord-blood-derived hematopoietic progenitor cell (HPC) products are FDA-approved in the U.S., for specific blood and immune disorders in specialist transplant settings. Most other donor products, including umbilical cord, Wharton's jelly, and perinatal tissue products sold by clinics, are not FDA-approved. Ask any provider to explain a product's FDA status.

No, using your own cells does not automatically make a treatment safe or approved. Procedures to collect and process cells carry their own considerations, and most clinic uses of self-derived cells are also not FDA-approved. A licensed clinician can discuss risks and alternatives with you.

Matching matters because a donor's cells and a recipient's immune system can interact. In transplant medicine, specialist teams evaluate this carefully. This is one reason such care belongs in hematology and transplant centers.

No, exosomes are tiny particles released by cells and are not the same as stem cells. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Ask a licensed clinician before considering one.

Verify the product's FDA status, check that any study is registered on ClinicalTrials.gov with IRB oversight, and confirm the clinician's license with your state medical board. Ask for written informed consent that covers risks and alternatives. Be cautious if you are asked to pay to join a trial or are promised results.

An exosome injection is a preparation of tiny cell-released particles that some clinics place into the skin, scalp or joints. The products vary in source and processing. No exosome product is FDA-approved in the U.S.

No, no exosome product is FDA-approved for any use. The FDA has warned the public about unapproved exosome and stem cell products. Ask any provider about the specific product's regulatory status.

No, they are different things, though they are often marketed together. Exosomes are particles released by cells, while stem cell therapy involves the cells themselves. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, used in specialist transplant settings.

The evidence is limited or investigational, so no one can promise results. Research on exosomes is ongoing, but laboratory interest does not prove a clinic product is safe or effective. A licensed clinician can discuss what is known and unknown.

Ask about the product's FDA status, its source and testing, and whether any study is registered on ClinicalTrials.gov with IRB oversight. Confirm the clinician's license with your state medical board and request written informed consent covering risks and alternatives.

Red flags include claims that a product cures or treats everything, paying to join a 'clinical trial', and testimonials used instead of evidence. Pressure to travel abroad or across states for treatment is another warning sign. Calling something 'holistic' does not change its FDA status.

Exosome IV therapy is a term clinics use for intravenous infusions of products said to contain exosomes, which are tiny particles released by cells. No exosome product is FDA-approved, and the FDA has warned the public about unapproved products. Talk with a licensed clinician about what is appropriate for you.

No, no exosome product is FDA-approved for any use. The FDA has issued public warnings about unapproved exosome and stem cell products. Ask any provider for the specific product's FDA status and verify it independently.

No, they are different, though they are often marketed together. Stem cell therapy involves cells, while exosomes are particles released by cells. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, used in specialist transplant settings.

Evidence in people is limited and largely investigational, so no outcome can be promised. Testimonials and marketing are not a substitute for well-designed, registered studies. A licensed clinician can explain what is and is not known.

Confirm the clinician's license with your state medical board and ask for the product's FDA status in writing. If a study is involved, look for registration on ClinicalTrials.gov and IRB oversight. Be cautious of cure-all claims, fees to join a "trial," or pressure to travel for treatment.

Ask about the product's source, manufacturer, and FDA status, plus the risks, alternatives, and limits of the evidence. Ask whether it is part of a registered study with IRB oversight, and request written informed consent. Only a licensed clinician can decide what is appropriate after an evaluation.

No. No exosome product is FDA-approved for hair or any other use, and the FDA has warned the public about unapproved exosome products. Ask any provider to explain the exact regulatory status of what they offer.

Exosomes for hair are preparations containing tiny cell-released particles that some clinics offer in connection with hair thinning. They are not FDA-approved, and evidence for hair use is limited and investigational.

There is no established evidence that exosomes reliably regrow hair, and no one can promise a result. Research is limited and ongoing, so discuss realistic expectations and proven alternatives with a licensed clinician.

No. Exosomes are small particles released by cells, while stem cells are living cells. Neither type of clinic product for hair is FDA-approved; the only approved stem-cell products in the U.S. are cord-blood-derived HPC products for certain blood and immune disorders.

Ask whether the product is FDA-approved, and check whether any study is registered on ClinicalTrials.gov with IRB oversight. Verify the clinician's license with your state medical board and request written informed consent covering risks and alternatives.

Watch for cure-all claims, charges to join a so-called clinical trial, testimonials in place of evidence, and pressure to travel for treatment. Any of these is a reason to pause and seek a second opinion from a licensed clinician.

Mesenchymal stem cells are living cells, while exosomes are tiny non-living particles that cells release. Exosomes carry molecules involved in cell signaling. Both are mostly investigational outside of approved uses.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome and stem cell products. Ask any provider about a product's regulatory status before considering it.

No, most clinic-offered MSC treatments are not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. These are used in specialist transplant settings.

No, exosomes are not stem cells, though they are sometimes marketed alongside stem cell therapy. Because they are not living cells, they are a different kind of product. Neither has been established as a proven treatment for the uses often advertised.

Verify the product's FDA status, and if it is described as a study, confirm it is registered on ClinicalTrials.gov with IRB oversight. Check the clinician's license with your state medical board and ask for written informed consent covering risks and alternatives. Be wary of cure-all claims and pressure to travel.

Be cautious, because paying to join a 'clinical trial' is a recognized red flag. Legitimate studies are registered, overseen by an IRB, and explain risks clearly. A licensed clinician can help you evaluate whether an offering is appropriate.

A fat stem cell injection is a procedure where fat tissue is collected from your body, processed, and injected into another area. The processed material often contains a mix of cell types, not only stem cells. It is generally not FDA-approved, so it is worth discussing with a licensed clinician.

No, fat-derived (adipose or SVF) stem cell injections are generally not FDA-approved in the U.S. The only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. The FDA has warned the public about unapproved stem cell products.

The evidence is limited and still developing for most uses, so no one can promise results. Some uses are being studied in clinical research. A licensed clinician can explain what is known and unknown for your situation.

Risks may include those linked to the fat collection procedure and the injection itself, such as pain, bleeding, or infection, as well as uncertainty about the product. A licensed clinician should review specific risks and alternatives with you in writing as part of informed consent.

Check whether the study is registered on ClinicalTrials.gov and has IRB oversight. Be wary of any program that asks you to pay to join a clinical trial. You can also verify the clinician's license with your state medical board.

Start with a licensed clinician, such as an orthopedic or regenerative medicine provider, who can evaluate your situation. Ask about FDA status, evidence, risks, and alternatives. Providers.plus lists licensed providers who may be a helpful starting point.

FDA-approved cord blood products are cord-blood-derived hematopoietic progenitor cell (HPC) products licensed for certain blood and immune disorders. They are used in specialist transplant settings. A licensed clinician decides whether one is appropriate after an evaluation.

Only a narrow category is: cord-blood-derived HPC products for certain blood and immune disorders. Most other stem cell therapy offered at clinics, including MSC, adipose/SVF and umbilical cord products, is not FDA-approved. The FDA has warned the public about unapproved products.

No, Wharton's jelly and other umbilical cord tissue products marketed by clinics are generally not FDA-approved. Evidence for many uses is limited or investigational. Ask any provider about the product's regulatory status.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products. Ask a licensed clinician about risks and alternatives before considering one.

Verify the product's FDA status, confirm the clinician's license with your state medical board, and get written informed consent covering risks and alternatives. If it is described as a study, check that it is registered on ClinicalTrials.gov with IRB oversight. Be wary of cure-all claims and of paying to join a trial.

A licensed clinician, typically a hematologist or transplant specialist, decides after a full evaluation. They can explain the approved uses, risks and alternatives. No outcome is guaranteed.

Holistic regenerative medicine is a descriptive term, not a formal medical specialty, for practices that combine whole-person wellness support with regenerative treatments. What it includes varies by clinic. It's worth asking any provider exactly what they mean and what each service's regulatory status is.

No single approval covers the term, because it describes a style of practice and not one product. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Most clinic stem cell therapy and all exosome products are not FDA-approved, and a "holistic" label doesn't change that.

Sometimes, but not always. Some practices offer stem cell therapy alongside lifestyle and integrative services, while others do not. If a practice offers it, ask whether the product is FDA-approved, whether it is part of a registered study, and what the risks and alternatives are.

Start by confirming the clinician's license with your state medical board. Then ask about the FDA status of any product, whether any study is registered on ClinicalTrials.gov with IRB oversight, and for written informed consent covering risks and alternatives. Providers.plus lists licensed providers you can explore.

Red flags include claims that a treatment cures or treats everything, being asked to pay to join a "clinical trial," testimonials used in place of evidence, and pressure to travel abroad or across states. Pressure to decide quickly is another reason to pause. You can always get a second opinion from another licensed clinician.

Yes, many people find that sleep, movement, nutrition, and stress support are valuable parts of overall wellbeing. Options like Somatic Experiences for body-based support or Therapists.plus for talk therapy may help some people. These do not replace the guidance of a licensed clinician.

Compare stem cell clinics by checking verifiable facts rather than marketing. Confirm the product's FDA status, the clinician's license with the state medical board, whether any study is registered on ClinicalTrials.gov with IRB oversight, and whether you receive written informed consent. A licensed clinician should evaluate you first.

Clinics themselves are not 'FDA-approved'; products are. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Most clinic stem cell, MSC, adipose, umbilical cord, Wharton's jelly and exosome offerings are not FDA-approved.

Red flags include claims that a treatment cures or treats everything, being asked to pay to join a 'clinical trial,' and testimonials used instead of evidence. Pressure to travel abroad or across states, or to decide quickly, is also a warning sign. The FDA has warned the public about unapproved stem cell products.

Search ClinicalTrials.gov to see whether the study is registered, and ask whether it has IRB oversight. Legitimate research generally explains risks openly and does not simply charge participants for access. A licensed clinician can help you interpret what you find.

Use your state medical board's website to look up the clinician's license, status and any public actions. Also ask about their training and experience with the specific procedure being offered. Providers.plus can also help you find licensed providers.

Ask whether the product is FDA-approved for your condition, what the risks and alternatives are, and what is known and unknown about the evidence. Request written informed consent to review at home. A good provider welcomes questions and does not promise results.

Informed consent for regenerative procedures is the process of a licensed clinician explaining a proposed treatment, its risks, unknowns, benefits, and alternatives so you can make a voluntary decision. It should include the product's regulatory status and be documented in writing. You should be free to ask questions and decline.

In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell therapy, including MSC, adipose/SVF, umbilical cord, Wharton's jelly, and perinatal products, is not FDA-approved. The FDA has warned the public about unapproved products.

It should describe the procedure, its purpose, possible risks, uncertainties, and reasonable alternatives, including not treating. It should also state whether the product is FDA-approved or investigational and who is responsible if complications occur. Ask for a copy to review before you sign.

Check whether the study is registered on ClinicalTrials.gov and whether it has IRB oversight. Be cautious if you are asked to pay to join a "clinical trial." A provider should be able to share the registration details and the consent document for the study.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products. Ask any provider offering them to explain their regulatory status and the risks in writing.

Confirm the clinician's license with your state medical board, which typically lists license status and any public disciplinary actions. You can also ask about their training and experience with the specific procedure. A second opinion from an independent licensed clinician may also help.

No, BMAC is not FDA-approved for orthopedic or joint uses. The only FDA-approved stem-cell products in the U.S. are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Ask any provider how they describe the regulatory status of what they offer.

Not exactly. BMAC is a concentrate of bone marrow that contains a mix of cell types and proteins, and only some of its cells may be stem or progenitor cells. It is often marketed as stem cell therapy, but that does not make it an FDA-approved product.

There is no reliable basis to promise that. Evidence for BMAC is limited and investigational, and no one can guarantee tissue regrowth or that surgery will be avoided. A licensed clinician can discuss your options and alternatives after an evaluation.

Some clinics rely on narrow exceptions in FDA rules or offer it as part of research. Those claims can be debated, so it is wise to ask how the clinic believes its use complies with FDA requirements and to request the details in writing.

Look for the study on ClinicalTrials.gov and ask whether an institutional review board (IRB) oversees it. Be cautious if you are asked to pay to join a "trial." Also confirm the clinician's license with your state medical board.

Ask about the product's FDA status, the evidence for your specific situation, the risks, and the alternatives. Request written informed consent that covers all of these. Only a licensed clinician can decide what is appropriate for you after an evaluation.

The difference is the amount of white blood cells (leukocytes) left in the final preparation. Leukocyte-rich PRP contains white blood cells above normal blood levels, while leukocyte-poor PRP has most of them removed. Both are made from your own blood but can differ in other ways too.

There is no established answer that one is better for everyone. Research is mixed, definitions vary, and evidence for many uses is limited or investigational. A licensed clinician can explain their reasoning for your situation after an evaluation.

Leukocytes are white blood cells, part of the immune system. In PRP, they are either kept or reduced depending on the equipment and method used. Researchers continue to study whether their presence matters and in what situations.

It depends on the specific product and use, so ask your provider. Centrifuge systems used to prepare PRP have been cleared for certain purposes, but that does not mean PRP is FDA-approved to treat a particular condition. Many uses are considered investigational or off-label.

No, PRP is not stem cell therapy. PRP concentrates platelets from your blood, while stem cell products involve different cell types. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, and the FDA has warned about unapproved stem cell and exosome products.

Ask which system they use, whether it is leukocyte-rich or leukocyte-poor, and why that suits your situation. Also ask about its FDA status, risks, alternatives, and what the written consent covers. Confirm their license with your state medical board.

The Lipogems procedure refers to the use of a commercial system that processes a person's own fat tissue so a clinician can use it in a chosen setting. It is a brand name, not a single standardized treatment. Whether it is appropriate for you is a decision for a licensed clinician after an evaluation.

It is often described that way, but the label can be misleading. Fat tissue contains many cell types, yet regulatory status depends on how the product is made and used. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders.

Ask your clinician to explain the exact FDA status for the specific use being proposed, because it can differ from the status of the device itself. Most clinic-based adipose and stem-cell treatments are not FDA-approved, and the FDA has warned the public about unapproved stem cell products. Request this information in writing.

Evidence for adipose-based approaches is limited or investigational for many uses, and no outcome can be promised. Individual situations differ, and experts hold different views. A licensed clinician can discuss what is known and unknown for your circumstances.

Ask about the product's FDA status, the evidence for your situation, the risks, and the alternatives, including not treating. Ask whether any study is registered on ClinicalTrials.gov with IRB oversight, and confirm the clinician's license with your state medical board. Get written informed consent before deciding.

Start by looking for licensed clinicians, such as those in orthopedic regenerative medicine, and verify their license with the state medical board. Directories like Providers.plus list licensed providers. Be cautious of anyone promising cures, pushing you to decide quickly, or asking you to pay to join a trial.

Mesenchymal stem cell treatment is the use of MSCs, or products made from them, with the aim of supporting the body's repair processes. Most uses are still being studied, and the evidence is limited or investigational. A licensed clinician decides what is appropriate after an evaluation.

No, not for most uses. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Most clinic MSC products are not FDA-approved, so ask your provider about the status of any product.

MSCs are described as coming from tissues such as bone marrow, fat tissue and umbilical cord tissue. The source and how the cells are processed can differ a lot between products. Ask a provider exactly what is used and what its regulatory status is.

Safety depends on the product, how it is made and who gives it, and unapproved products carry unknowns. The FDA has warned the public about unapproved stem cell products. Ask a licensed clinician about risks and alternatives, and get written informed consent.

Check that any study is registered on ClinicalTrials.gov and has IRB oversight, and confirm the clinician's license with your state medical board. Be cautious of cure-all claims, fees to join a 'trial', testimonials in place of evidence, and pressure to travel. Get the risks and alternatives in writing.

No. Exosomes are tiny particles released by cells, and they are not the same as the cells themselves. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products.

Stem cells are a broad category of cells that can renew themselves and give rise to other cell types, while mesenchymal stromal cells are one specific kind of cell often grouped under that umbrella. Many researchers use "stromal" because lab-grown MSC populations are mixed and may not all act as true stem cells. Not every stem cell is an MSC.

The two names are used for the same general type of cell, but "stromal" is the more cautious scientific term. "Mesenchymal stem cells" is the older name and is still widely used, including in marketing. The naming difference does not change a product's FDA status.

No, most MSC treatments offered by clinics are not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask a provider about any product's status.

No, stem cell therapy is a broad phrase and MSC therapy refers to just one kind of cell product. Blood-forming stem cell transplants are very different from clinic-based MSC, adipose, or umbilical cord products. Ask exactly which cells are used and whether they are FDA-approved or part of a registered study.

They can be taken from tissues such as bone marrow, fat, and umbilical cord material. The source and how cells are processed can vary, which is one reason products are not interchangeable. A licensed clinician can explain what a specific product contains and its regulatory status.

Verify the product's FDA status, confirm the study is registered on ClinicalTrials.gov with IRB oversight, and check the clinician's license with your state medical board. Ask for written informed consent that covers risks and alternatives. Be wary of cure-all claims, fees to join a "trial," testimonials instead of evidence, and pressure to travel for treatment.

Microfragmented adipose tissue (MFAT) is a person's own fat tissue that has been collected and processed into smaller fragments. It keeps some of the natural structure of fat and is discussed in regenerative medicine and stem cell therapy conversations. Its use for most conditions is considered limited or investigational.

No, microfragmented adipose tissue is not FDA-approved as a stem cell therapy for treating joint or other conditions. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Ask any provider to explain the regulatory status of what they offer.

Not exactly. MFAT is processed fat tissue that contains a mix of components, including some cells sometimes called MSCs, and it is often discussed alongside stem cell therapy. It is not the same as FDA-approved HPC transplant products, and the terms are sometimes used loosely in marketing.

MFAT keeps fat in small fragments with much of its natural structure, while stromal vascular fraction (SVF) generally refers to a cell mix separated from fat tissue. Both are adipose-derived approaches, and most clinic uses of either are not FDA-approved. A licensed provider can explain how a specific clinic describes its process.

There is no reliable basis to claim that microfragmented adipose tissue regrows cartilage or avoids surgery. Evidence is limited and investigational, and individual results vary. Be cautious of any clinic that promises these outcomes.

Start with a licensed clinician and confirm their license with your state medical board. Ask whether the procedure is FDA-approved, whether any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Directories like Providers.plus list licensed providers you can research.

Side effects vary by product, preparation and person, and reliable information is often limited. General injection-related concerns that clinicians discuss include pain, swelling or infection at the injection site and reactions to materials used. A licensed clinician can explain the risks that may apply to you.

Most are not. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask any provider about a product's status.

No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Safety and effectiveness have not been established for clinic use. Talk with a licensed clinician before considering any such product.

Check the clinician's license with your state medical board, ask about the product's FDA status, and look for any study on ClinicalTrials.gov with IRB oversight. Be cautious of cure-all claims, fees to join a 'clinical trial', and testimonials used in place of evidence. Request written informed consent that covers risks and alternatives.

Ask whether the product is FDA-approved, what the known and unknown risks are, and what alternatives exist for your situation. Ask who handles follow-up if you have a problem. A licensed clinician should answer clearly and put consent information in writing.

Contact your clinician promptly about any symptom that worries you, and call 911 for emergencies. This page cannot assess symptoms or give medical advice. If you are in emotional crisis, call or text 988.

MSC therapy for joints is the use of mesenchymal stem or stromal cells in an attempt to support a joint affected by wear, injury or inflammation. In the U.S. these uses are not FDA-approved and remain investigational. A licensed clinician can explain what is known and unknown.

No, MSC therapy for joints is not FDA-approved in the U.S. The only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. The FDA has also warned the public about unapproved stem cell products.

There is no established evidence that MSC therapy regrows cartilage, and no clinic should promise it. Research is ongoing and the evidence is limited. Ask any provider to explain plainly what is and isn't known.

No one can promise that it will. Whether surgery or another option is appropriate depends on your individual situation, which an orthopedic clinician can evaluate. Be cautious of any claim that a treatment avoids surgery.

No, exosomes are tiny particles released by cells, not whole cells. No exosome product is FDA-approved, and the FDA has warned about unapproved exosome products. Ask a provider about the product's regulatory status before considering it.

Confirm the clinician's license through your state medical board and look up any study on ClinicalTrials.gov to see that it is registered and has IRB oversight. Ask for written informed consent covering risks and alternatives. Be wary of paying to join a 'clinical trial' or of pressure to travel for treatment.

Orthobiologics for sports injuries are biologic substances, such as platelet-rich plasma or cell-based preparations, that some clinicians discuss for joint, tendon, or muscle problems. Evidence for many uses is limited or investigational. A licensed clinician can explain what applies to your situation.

No, not for sports injuries. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell treatments are not FDA-approved, so ask any provider about a product's status.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome products. Be cautious of any clinic that markets them as a proven treatment.

No one can promise that. Whether surgery is needed depends on your diagnosis and a clinician's evaluation, and orthobiologics are not established as a replacement for surgery. Ask your provider to explain all alternatives, including surgery and rehab.

Start with a licensed physician, such as a sports medicine or orthopedic specialist, and confirm their license with your state medical board. Ask whether products are FDA-approved and whether any study is registered on ClinicalTrials.gov with IRB oversight. Request written informed consent covering risks and alternatives.

Red flags include claims that a treatment cures or treats everything, fees to join a 'clinical trial,' reliance on testimonials instead of evidence, and pressure to travel abroad or across states. A trustworthy provider is open about uncertainty and regulatory status. If something feels rushed, pause and get a second opinion.

A perinatal tissue allograft is a product made from donated birth-related tissue, such as amniotic membrane, umbilical cord or placenta, used in another person. Products differ in how they are processed and what they contain. Their regulatory status depends on the product and its intended use.

Most are not FDA-approved for treating injuries or diseases. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Ask your provider to explain the specific product's FDA status.

Not necessarily. Some products are marketed as stem cell therapy, but processed perinatal tissue may contain few or no living cells despite the labeling. Ask the provider for documentation of what the product actually contains and whether it is FDA-approved.

No. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome and stem cell products. Be cautious about any clinic that offers them as proven treatments.

Verify the product's FDA status, confirm the clinician's license with your state medical board, and ask for written informed consent covering risks and alternatives. If it is described as research, check that the study is registered on ClinicalTrials.gov with IRB oversight.

No one can promise that. Evidence for many uses is limited or investigational, and only a licensed clinician can advise on appropriate options after an evaluation. Be wary of any claim that a treatment avoids surgery or regrows tissue.

PRP for knee arthritis is an injection of platelet-rich plasma, made from your own blood, into the knee joint. It is used by some clinicians in discussions of osteoarthritis care, but it is generally an off-label or investigational use. A licensed clinician can explain whether it fits your situation.

No, PRP is generally not FDA-approved as a treatment for knee arthritis. The devices used to prepare PRP may be FDA-cleared for preparing the concentrate, but that is different from approval for treating a condition. Ask your provider to explain the regulatory status in plain terms.

The evidence is limited and mixed, and no outcome can be promised. Researchers continue to study it, and results may vary between people and preparations. A licensed clinician can describe what is and is not known.

No, PRP is not stem cell therapy. PRP concentrates platelets from your blood, while stem cell products involve different types of cells. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell products for certain blood and immune disorders, and the FDA has warned about unapproved stem cell and exosome products.

Start by asking about the product's FDA status, the provider's license, and the risks and alternatives. Ask whether any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent. Be wary of cure-all claims, paying to join a 'clinical trial', and pressure to travel for treatment.

PRP for knee arthritis is offered by some sports medicine, orthopedic and regenerative medicine clinicians. Providers.plus lists licensed providers you can explore. Always confirm credentials with your state medical board and have an evaluation first.

PRP hair restoration sessions are clinic visits where a clinician prepares platelet-rich plasma from your own blood and uses it on the scalp in an effort to support hair thinning. The approach is generally off-label and the evidence is still limited. A licensed clinician decides whether it is appropriate.

There is no single number that applies to everyone, and this page does not recommend one. The number and spacing of visits is a decision for a licensed clinician after an evaluation. Ask any provider to explain their reasoning and how progress would be assessed.

PRP for hair loss is not an FDA-approved treatment indication, so its use is generally considered off-label. The centrifuge devices used to prepare PRP may be cleared for other purposes, which is different from approval for hair restoration. Ask your provider to explain the regulatory status plainly.

No, PRP is not stem cell therapy. PRP concentrates platelets from your blood, while stem cell products involve different cell types. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, and the FDA has warned about unapproved stem cell and exosome products.

Ask about the provider's license, training, the preparation method, risks, alternatives and the honest state of the evidence. Request written informed consent. Verify the clinician's license with your state medical board.

Red flags include claims that a treatment cures or treats everything, testimonials used instead of evidence, and being asked to pay to join a 'clinical trial'. Pressure to travel across states or abroad is another warning sign. Legitimate studies are registered on ClinicalTrials.gov and have IRB oversight.

PRP injection aftercare is the set of instructions a licensed clinician gives you after a platelet-rich plasma procedure. It usually covers caring for the treated area, activity, medications to discuss, and when to call the clinic. The details vary by provider and by the area treated, so follow your own clinician's guidance.

Some people report soreness, swelling or tenderness at the site, and clinicians often describe this as something to expect for certain procedures. Whether it is ordinary for you is a question for your provider. Contact them if symptoms seem strong, worsen or concern you.

Yes, ask your provider which medications and supplements, including pain relievers, you should discuss before and after your procedure. Advice differs from person to person based on health history. Do not change any medication without checking with your licensed clinician.

There is no single timeline, because it depends on the clinician, the body area and your situation. Your provider should tell you what to expect and give you instructions in writing. Ask when follow-up is planned and whom to contact with questions.

PRP is made from your own blood using devices that are generally cleared for certain uses, but many specific uses of PRP are off-label or investigational, and the evidence is limited or still developing. PRP is not a stem-cell product, and the only FDA-approved stem-cell products in the U.S. are cord-blood-derived HPC products for certain blood and immune disorders. Ask your provider about the FDA status of your specific use.

Start by confirming the clinician's license with your state medical board and asking about their experience with your type of concern. Ask for written informed consent covering risks and alternatives, and check that any study is registered on ClinicalTrials.gov with IRB oversight. Directories such as Providers.plus list licensed providers you can explore.

A PRP injection for tendons is a procedure in which a clinician concentrates platelets from your own blood and places them near an affected tendon. Whether it is appropriate depends on an evaluation by a licensed clinician. Evidence for tendon use is limited and still developing.

No, PRP is a blood-derived concentrate of platelets, while stem cell products involve cells. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. Most clinic stem cell and exosome offerings are not FDA-approved, so ask any provider about the status of what they offer.

Research is ongoing, and the evidence is limited and mixed for some tendon uses. Experiences vary, and no outcome can be promised. A licensed clinician can explain what is known for your specific situation.

Ask about the FDA status of the product and its preparation, the evidence for your condition, the risks, and the alternatives. Confirm the clinician's license with the state medical board and request written informed consent. If a study is involved, check that it is registered on ClinicalTrials.gov with IRB oversight.

PRP is offered by some clinicians in sports medicine, orthopedics, and regenerative medicine practices. Credentials and experience vary, so verify the license and ask about training. You can browse licensed providers through Providers.plus.

Be cautious of cure-all claims, testimonials in place of evidence, and requests to pay to join a 'clinical trial'. Pressure to travel abroad or across states is also a warning sign. Calling a treatment 'holistic' or 'alternative' does not change its FDA status.

Start by asking whether the product is FDA-approved for your condition, and what its regulatory status is if it is not. Then ask about the doctor's license and training, the risks, the alternatives, and what follow-up care looks like. Ask for everything in writing, including the consent form.

Only in limited cases. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell, MSC, adipose/SVF, umbilical cord, Wharton's jelly and exosome products are not FDA-approved, and the FDA has warned the public about them.

Look up the clinician on your state medical board's website to confirm that the license is active and to see any public actions. You can also ask about board certification and training. A reputable provider will be glad to share this information.

Check that the study is registered on ClinicalTrials.gov and that it has IRB (institutional review board) oversight. Be cautious if you are asked to pay to join a "clinical trial", since that can be a red flag. Ask the study team to explain the risks, the purpose, and your right to leave.

Watch for cure-all or "treats everything" claims, testimonials used in place of evidence, and pressure to decide quickly. Pressure to travel abroad or across states for treatment is another warning sign. Also be wary of any promise of results, since no honest provider can guarantee them.

Yes, a second opinion is a sensible step for any significant health decision. A different licensed clinician can review your records, explain established options, and help you weigh the risks and alternatives. A trustworthy provider will support this.

The biggest warning signs include cure-all or "treats everything" claims, testimonials used in place of evidence, and pressure to decide quickly. Others include being charged to join a "clinical trial" and vague answers about FDA status. Any one of these is a good reason to pause and ask more questions.

Only a narrow set of stem-cell products is FDA-approved in the U.S.: cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell therapy offerings are not FDA-approved. Ask any provider to explain the regulatory status of what they are proposing.

No, no exosome product is FDA-approved. The FDA has warned the public about unapproved exosome and stem cell products. If a clinic offers exosomes, ask what the product is, where it comes from, and whether it is part of a registered study.

Start by confirming the clinician's license with your state medical board. Then ask whether the product is FDA-approved and whether any study is registered on ClinicalTrials.gov with IRB oversight. Request written informed consent that covers risks and alternatives, and consider a second opinion.

Paying to join a so-called clinical trial is a red flag. Legitimate research is typically registered on ClinicalTrials.gov, overseen by an IRB, and explained through formal informed consent. Ask for the registration details and review them before agreeing to anything.

No, calling a practice holistic or alternative does not change the FDA status of a product. The same questions apply: is it approved, is it part of a registered study, and is the clinician licensed? Integrative practices can be thoughtful partners when they are open about these answers.

A regenerative injection for back pain is a general term for injected products, such as PRP, cell-based preparations, or prolotherapy, that some clinics offer for spine-related pain. The term covers very different products with different regulatory status. Most cell-based and exosome products used this way are not FDA-approved, and evidence is limited or investigational.

No, stem cell therapy for back pain is not FDA-approved in the U.S. The only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Ask any provider to explain the FDA status of what they offer.

No one can promise that a regenerative injection will avoid surgery. Evidence for these injections in back pain is limited, and whether surgery is needed depends on your specific condition. A licensed spine specialist can evaluate you and explain the options and alternatives.

No, no exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. If a clinic offers them, ask about the product's source, its regulatory status, and whether it is part of a registered study with IRB oversight.

Start by confirming the clinician's license with your state medical board and asking about training in spine or musculoskeletal care. Ask for written informed consent that covers risks and alternatives, and check whether any study is registered on ClinicalTrials.gov. Be cautious of cure-all claims, testimonials in place of evidence, and pressure to travel for treatment.

Ask whether the product is FDA-approved for your condition, what the risks and alternatives are, and what evidence supports its use. Also ask how the provider will evaluate the cause of your pain and what non-injection options exist. A trustworthy provider welcomes these questions.

Regenerative medicine for hair restoration is an umbrella term for biologic approaches, such as PRP, cell-based products and exosomes, that are marketed for hair thinning. Evidence for these uses is limited or investigational. A licensed clinician can explain what applies to your situation.

No, stem cell therapy for hair loss is not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. The FDA has warned the public about unapproved stem cell products.

No, no exosome product is FDA-approved for any use, including hair. The FDA has issued public warnings about unapproved exosome products. Ask any provider offering them to explain the product's source and regulatory status in writing.

PRP is often grouped under regenerative medicine because it uses components from your own blood. Its use for hair is generally considered an area with limited or still-developing evidence. A licensed clinician can discuss whether it is appropriate for you.

Start by confirming the clinician's license with your state medical board and asking about training in hair and scalp conditions. Providers.plus lists licensed providers you can review. Ask about the product's FDA status and request informed consent in writing.

Red flags include claims of curing everything, fees to join a 'clinical trial', testimonials used instead of evidence, and pressure to travel abroad or across states. Legitimate studies are registered on ClinicalTrials.gov with IRB oversight. When in doubt, get a second opinion from another licensed clinician.

Regenerative medicine for knee pain is a general term for biologic treatments, such as PRP, bone marrow or fat-derived preparations, and stem cell therapy products, that are used in or near the knee. The term covers very different products with different regulatory status and evidence. A licensed clinician can explain what is being offered and why.

No, stem cell therapy for the knee is not FDA-approved in the U.S. The only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Most clinic offerings for joints are unapproved, so ask any provider about the product's FDA status.

No one can promise that. Evidence for these uses in the knee is limited or investigational, and claims of cartilage regrowth or avoiding surgery should be treated with caution. A licensed orthopedic or sports medicine clinician can discuss realistic options for your situation.

No, no exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. If a clinic offers them, ask what the product is, where it comes from and whether it is part of a registered study with IRB oversight.

Start by confirming the clinician's license with your state medical board and asking about the FDA status of every product. Look for clear written informed consent, honest discussion of risks and alternatives, and no pressure to decide quickly. Directories like Providers.plus can help you find licensed providers to compare.

Ask what the product is, whether it is FDA-approved for this use, and whether it is part of a study registered on ClinicalTrials.gov with IRB oversight. Also ask about risks, alternatives, and what happens if it does not help. Be cautious if you are asked to pay to join a "trial" or told it works for everything.

The evidence is limited or investigational, and no outcome can be promised. Most clinic stem cell products used for shoulders are not FDA-approved for rotator cuff problems. A licensed clinician can explain what is known and unknown for your situation.

No, not for the rotator cuff. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell and exosome products.

There is no established proof that stem cell injections regrow rotator cuff tissue, and anyone claiming so should be questioned. Evidence is limited and investigational. A licensed orthopedic or sports medicine clinician can discuss realistic options.

No treatment can be promised to avoid surgery. Whether surgery is appropriate depends on your exam, imaging, and goals, as judged by a licensed clinician. Be cautious of any claim that an unapproved product replaces surgery.

No. No exosome product is FDA-approved, and the FDA has issued public warnings about them. Ask any provider offering exosomes about the product's source, regulatory status, and risks.

Start with a licensed clinician, such as an orthopedic, sports medicine, or regenerative medicine provider, and verify their license with your state medical board. Ask whether any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Be wary of cure-all claims, fees to join a "trial," and pressure to travel.

Stem cell skin rejuvenation is a marketing term for aesthetic services said to use cells or cell-derived products to support the appearance of skin. It is not one standardized procedure, and contents vary widely. Ask a licensed provider exactly what is used and what its regulatory status is.

No, most stem cell skin rejuvenation offerings are not FDA-approved. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders. The FDA has also warned the public about unapproved stem cell and exosome products.

No, no exosome product is FDA-approved. The FDA has issued public warnings about unapproved exosome products. Ask any provider to explain the product's source and status in writing.

Evidence for stem cell therapy for cosmetic skin purposes is limited and largely investigational. Researchers continue to study the area, but no outcome can be promised. A licensed clinician can explain what is and isn't established.

Confirm the clinician's license with your state medical board, and verify the product's FDA status. If a study is offered, look for registration on ClinicalTrials.gov with IRB oversight. Ask for written informed consent that covers risks and alternatives.

Warning signs include cure-all claims, charging you to join a "clinical trial," relying on testimonials instead of evidence, and pressure to travel abroad or across states. Holistic or alternative framing also does not change FDA status. If something feels rushed, pause and seek a second opinion.

The main stem cell tourism risks include receiving products that are not FDA-approved, unknown product quality or contamination, unproven claims, and limited follow-up care. Legal protections and oversight can also be harder to rely on when treatment happens far from home. A licensed clinician can help you weigh these before you decide.

In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. Most clinic stem cell and exosome products are not FDA-approved, and the FDA has warned the public about them. Ask any provider to explain the regulatory status of what they offer.

Start by confirming the clinician's license with your state medical board and asking whether the product is FDA-approved for the stated use. If the clinic says it is running a study, look for it on ClinicalTrials.gov and ask about IRB oversight. Request written informed consent that covers risks and alternatives.

No one can promise safety, and traveling abroad can add risks such as different product standards, language barriers, and limited follow-up care. Talk with your own licensed clinician before making plans, and be cautious if you feel pressured to travel. Verify the product and the provider carefully.

Common red flags include claims that a treatment cures or 'treats everything', asking you to pay to join a 'clinical trial', and relying on testimonials instead of evidence. Pressure to decide quickly or to travel across states or abroad is another warning sign. Calling a treatment 'holistic' does not change its FDA status.

Ask whether the specific product is FDA-approved for your situation, what the evidence is, and what established alternatives exist. Also ask who would provide follow-up care and what to do if complications arise. Your clinician can help you evaluate the information, though decisions are made after a proper evaluation.

Stromal vascular fraction (SVF) is a mixture of cells and other components obtained by processing fat tissue and removing the fat cells. It contains several cell types rather than one purified cell. It is often discussed within stem cell therapy, but that does not mean it is proven for any condition.

No, SVF is not an FDA-approved product. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Ask any provider about the FDA status of what they offer.

Not exactly. SVF is a mixed cell preparation from fat that is sometimes described as containing stem-cell-like cells, and it is often marketed under the stem cell therapy label. It is not a purified stem cell product, and most such clinic uses are not FDA-approved.

There is no established evidence that SVF regrows cartilage or tissue, or that it replaces surgery. Evidence is limited or investigational, and any claim otherwise deserves caution. A licensed clinician can discuss your options and alternatives after an evaluation.

Look for the study on ClinicalTrials.gov and confirm it has IRB oversight. Be wary of any program that asks you to pay to join a 'clinical trial'. Also confirm the clinician's license with your state medical board and request written informed consent.

Ask whether the product is FDA-approved, what the risks and alternatives are, and whether it is offered within a registered study. Ask what the consent form covers and how your care would be followed up. A trustworthy provider will answer plainly and without pressure.

Umbilical cord stem cell therapy is a term for treatments that use cells from cord blood or cord tissue. The only FDA-approved versions in the U.S. are cord-blood-derived hematopoietic progenitor cell products for certain blood and immune disorders. Many other products sold under this name are not FDA-approved.

Only cord-blood-derived HPC products are FDA-approved, and they are used in specialist transplant settings for certain blood and immune disorders. Most clinic products made from Wharton's jelly, cord tissue or other perinatal sources are not approved. Ask any provider directly about the FDA status of what they offer.

No, Wharton's jelly and similar cord tissue products offered at clinics are generally not FDA-approved. The FDA has warned the public about unapproved stem cell products. Evidence for their use is limited or investigational, so discuss risks and alternatives with a licensed clinician.

No, no exosome product is FDA-approved. The FDA has issued public warnings about unapproved exosome products. If a clinic offers them, ask what evidence exists and whether a registered, IRB-overseen study is involved.

Confirm the clinician's license with your state medical board and ask about the product's FDA status. If a study is involved, look for it on ClinicalTrials.gov and ask about IRB oversight. Request written informed consent that explains risks and alternatives.

Warning signs include claims to cure or treat everything, paying to join a 'clinical trial', testimonials used instead of evidence, and pressure to travel abroad or across states. Calling a treatment holistic or alternative does not change its FDA status. A licensed clinician can help you weigh any offer.

Start by searching for the study on ClinicalTrials.gov and confirming it is registered. Then ask which IRB oversees it, whether the product is FDA-approved or studied under FDA oversight, and whether the clinician's license checks out with the state medical board. A licensed clinician can help you review what you find.

No, a registration is a good first step but not proof of quality. You should also confirm IRB oversight, the FDA status of the product and the clinician's license. Written informed consent that describes risks and alternatives is another key check.

An IRB, or Institutional Review Board, is an independent group that reviews a study to help protect participants. Ask the study team for the IRB's name and how to contact it. A legitimate study should be able to tell you.

Be cautious, because being asked to pay to join a "trial" is a recognized red flag. Legitimate research does exist, and costs vary by study. Ask a licensed clinician and the study team to explain any charges in writing before you agree to anything.

In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Most clinic stem cell therapy offerings, including MSC, adipose/SVF, umbilical cord, Wharton's jelly, perinatal and exosome products, are not FDA-approved. The FDA has warned the public about unapproved products.

Use your state medical board's public license lookup to confirm the license is active and to see any disciplinary actions. Ask for the clinician's full name and license details. Also ask who oversees the study and how to reach them.

Wharton's jelly stem cells are cells, usually described as mesenchymal stromal cells, found in the gel-like tissue inside the umbilical cord. They are studied in laboratories and investigational settings. Products marketed with this name vary widely and are generally not FDA-approved.

No, Wharton's jelly products offered by clinics are generally not FDA-approved. In the U.S., the only FDA-approved stem cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders. Ask any provider to explain the exact FDA status of a product.

No, they are different. Cord blood is the blood remaining in the umbilical cord and placenta, and certain cord blood products are FDA-approved for specific blood and immune disorders. Wharton's jelly is the gel-like tissue surrounding the cord's vessels.

Evidence for clinic-offered Wharton's jelly treatments is limited and largely investigational. No one can promise results, and a licensed clinician can explain what is and is not known for your situation.

Verify the product's FDA status, confirm the clinician's license with your state medical board, and ask for written informed consent covering risks and alternatives. If a study is mentioned, check that it is registered on ClinicalTrials.gov with IRB oversight. Be wary of cure-all claims, fees to join a 'trial', and reliance on testimonials.

Ask whether the product is FDA-approved, how it was sourced and processed, what the risks and alternatives are, and what oversight applies. Also ask whether it is part of a registered study. A good provider will answer clearly and give you time to decide.

Exosomes in regenerative medicine are tiny particles released by cells that carry molecules such as proteins and genetic material. Researchers study them as a possible way cells communicate. Their use in treatments is largely investigational.

No, exosomes are not stem cells. They are non-living particles that cells release, while stem cells are living cells. Products labeled as either can vary greatly, so ask a provider about the source and regulatory status.

No exosome product is FDA-approved. The FDA has warned the public about unapproved exosome and stem cell products. Ask any provider to explain the product's FDA status in writing.

Safety depends on the specific product, how it is made, and how it is used, and it is not established for many marketed exosome products. Because they are unapproved, they have not gone through FDA review for safety and effectiveness. Only a licensed clinician can discuss risks for your situation.

Confirm the clinician's license with your state medical board and ask whether the product is FDA-approved. If it is offered as research, check that the study is registered on ClinicalTrials.gov with IRB oversight. Request written informed consent that covers risks and alternatives.

Red flags include claims that a treatment cures or treats everything, being asked to pay to join a 'clinical trial', and relying on testimonials instead of evidence. Pressure to travel abroad or across states is another warning sign. Calling a treatment 'holistic' or 'alternative' does not change its FDA status.

Mesenchymal stem cells (MSCs) are adult stem cells found in tissues such as bone marrow, fat and umbilical cord. In the lab they can develop into cell types like bone, cartilage and fat cells. Their use in people is mostly investigational.

They have been described in bone marrow, adipose (fat) tissue and perinatal tissues such as umbilical cord and Wharton's jelly. Where a product comes from does not by itself make it approved or proven. Ask any provider about the source and how the product is regulated.

No, most are not. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived hematopoietic progenitor cell (HPC) products for certain blood and immune disorders, used in specialist transplant settings. The FDA has warned the public about unapproved stem cell products, so ask any provider about a product's FDA status.

No. MSCs are living cells, while exosomes are tiny particles that cells release. No exosome product is FDA-approved, and the FDA has warned the public about unapproved exosome products. Talk with a licensed clinician before considering either.

Check that the study is registered on ClinicalTrials.gov and has IRB oversight. Be cautious if you are asked to pay to join a clinical trial. Also ask for written informed consent that explains the risks and alternatives.

Ask whether the product is FDA-approved for your situation, what the evidence is and where it is limited, and what the risks and alternatives are. Confirm the clinician's license with your state medical board. Get written informed consent and feel free to seek a second opinion.

Bone marrow aspirate concentrate (BMAC) is a preparation made from a person's own bone marrow fluid that has been spun in a centrifuge to concentrate certain components. It is discussed in orthopedic and sports medicine settings. It is not an FDA-approved product for joint or tendon uses, and evidence is limited or investigational.

BMAC is often marketed as stem cell therapy, but the two terms are not identical. BMAC contains a mix of components, including small numbers of cells described as stem or progenitor cells. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders.

No, BMAC for musculoskeletal uses is not an FDA-approved product. The FDA has warned the public about unapproved stem cell products. Ask any provider about the regulatory status of what they offer and whether it is part of a registered study.

It is typically drawn from inside a bone, commonly the hip, by a clinician. The fluid is then processed to concentrate some of its components. A licensed clinician decides whether any such procedure is appropriate after an evaluation.

Evidence is limited and still being studied, so no one can promise a result. Different people and conditions may respond differently, and research continues. A licensed clinician can explain what is and is not known for your situation.

Start with a licensed clinician in orthopedic regenerative medicine or sports medicine, and confirm their license with your state medical board. Ask about FDA status, whether any study is registered on ClinicalTrials.gov with IRB oversight, and request written informed consent covering risks and alternatives. Providers.plus lists licensed providers you can explore.

PRP therapy uses platelet-rich plasma, a concentrate made from a person's own blood, which a clinician may use in certain orthopedic, sports medicine, aesthetic, or hair-related settings. Blood is drawn, spun to concentrate the platelets, and then used by the clinician. Many uses are off-label or investigational, so it is best to discuss it with a licensed clinician.

No, PRP is not a stem cell therapy. PRP concentrates platelets and plasma from your blood, while stem cell products involve different cell types. In the U.S., the only FDA-approved stem-cell products are cord-blood-derived HPC products for certain blood and immune disorders, used in specialist transplant settings.

The FDA has cleared certain devices used to prepare PRP, but that is not the same as approving PRP as a treatment for a specific condition. Many uses are considered off-label or investigational. Ask your provider to explain the regulatory status of both the device and the intended use.

PRP is typically made from your own blood, drawn by a clinician or trained staff member. This is called an autologous preparation. The exact way it is prepared can differ between practices, so it is reasonable to ask how it is made.

The evidence varies by use and is still developing, and results are not guaranteed. Some uses have been studied more than others, and findings have been mixed or limited for many. A licensed clinician can explain what is known and not known for your situation.

Start by looking for a licensed clinician, such as through Providers.plus, and confirm their license with your state medical board. Ask about evidence, risks, alternatives, and written informed consent. Be cautious of cure-all claims, testimonials in place of evidence, or pressure to pay quickly or travel for care.